Haizheng Pharmaceutical announced that the cumulative deviation value of the closing price increase of the company's A-share shares reached more than 20% on October 19 and October 20, 2026 for two consecutive trading days, which is an abnormal fluctuation in stock trading. After self-inspection and inquiries, with the controlling shareholders and actual controllers, apart from Guomao Group, a shareholder holding 5% or more of the shares, which is still being processed, there are no other important matters that should be disclosed but not disclosed. The company's production and operation are normal, no media reports or market rumors have been discovered that have had a significant impact on the stock price, and the directors, supervisors, and controlling shareholders and actual controllers did not trade the company's shares during the change period. Investors are kindly requested to pay attention to investment risks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.